Cargando…

Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings

INTRODUCTION: The management of neuromuscular blockade (NMB) has evolved over time and remains a critical component of general anesthesia. However, NMB use varies by patient and procedural characteristics, clinical practices, protocols, and drug access. National utilization patterns are unknown. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Bash, Lori D., Turzhitsky, Vladimir, Black, Wynona, Urman, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317140/
https://www.ncbi.nlm.nih.gov/pubmed/34319550
http://dx.doi.org/10.1007/s12325-021-01835-2
_version_ 1783730012321480704
author Bash, Lori D.
Turzhitsky, Vladimir
Black, Wynona
Urman, Richard D.
author_facet Bash, Lori D.
Turzhitsky, Vladimir
Black, Wynona
Urman, Richard D.
author_sort Bash, Lori D.
collection PubMed
description INTRODUCTION: The management of neuromuscular blockade (NMB) has evolved over time and remains a critical component of general anesthesia. However, NMB use varies by patient and procedural characteristics, clinical practices, protocols, and drug access. National utilization patterns are unknown. We describe changes in NMB and NMB reversal agent administration in surgical inpatients since the US introduction of sugammadex in December 2015. METHODS: In a retrospective observational study of inpatients involving NMB with rocuronium or vecuronium in the Premier Healthcare Database, we estimate associations between factors related to choice of (1) active NMB reversal versus spontaneous recovery and (2) sugammadex versus neostigmine as the reversal agent. RESULTS: Among 4.3 million adult inpatient encounters involving rocuronium or vecuronium, the most widely administered NMB agent was rocuronium alone (86%). Over time, gradual declines in both neostigmine use and spontaneous reversal were observed (64% and 36% in 2014 to 38% and 28%, respectively in the first half of 2019). Several factors were independently associated with use of active versus spontaneous NMB recovery including years since 2016, patient (age, race, comorbidities), and procedure (admission and surgery type) characteristics. Among those actively reversed, these and other factors were independently associated with choice of reversal agent administered, including size and teaching affiliation of hospital. While both impacted choices in treatment, the direction and magnitude of effect of patient comorbidities and procedure type varied in their impact on choice of mode (pharmacologic vs. spontaneous) and agent (neostigmine vs. sugammadex) of NMB reversal independent of other factors and each other. Sites which adopted sugammadex earlier were more likely to choose sugammadex over neostigmine compared with later adopters independent of other factors. CONCLUSIONS: Among US adult inpatients administered NMBs, we observed complex relationships between patient, site, procedural characteristics, and NMB management choices as NMBA choice and active reversal options among inpatient cases changed over time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01835-2.
format Online
Article
Text
id pubmed-8317140
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-83171402021-07-28 Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings Bash, Lori D. Turzhitsky, Vladimir Black, Wynona Urman, Richard D. Adv Ther Original Research INTRODUCTION: The management of neuromuscular blockade (NMB) has evolved over time and remains a critical component of general anesthesia. However, NMB use varies by patient and procedural characteristics, clinical practices, protocols, and drug access. National utilization patterns are unknown. We describe changes in NMB and NMB reversal agent administration in surgical inpatients since the US introduction of sugammadex in December 2015. METHODS: In a retrospective observational study of inpatients involving NMB with rocuronium or vecuronium in the Premier Healthcare Database, we estimate associations between factors related to choice of (1) active NMB reversal versus spontaneous recovery and (2) sugammadex versus neostigmine as the reversal agent. RESULTS: Among 4.3 million adult inpatient encounters involving rocuronium or vecuronium, the most widely administered NMB agent was rocuronium alone (86%). Over time, gradual declines in both neostigmine use and spontaneous reversal were observed (64% and 36% in 2014 to 38% and 28%, respectively in the first half of 2019). Several factors were independently associated with use of active versus spontaneous NMB recovery including years since 2016, patient (age, race, comorbidities), and procedure (admission and surgery type) characteristics. Among those actively reversed, these and other factors were independently associated with choice of reversal agent administered, including size and teaching affiliation of hospital. While both impacted choices in treatment, the direction and magnitude of effect of patient comorbidities and procedure type varied in their impact on choice of mode (pharmacologic vs. spontaneous) and agent (neostigmine vs. sugammadex) of NMB reversal independent of other factors and each other. Sites which adopted sugammadex earlier were more likely to choose sugammadex over neostigmine compared with later adopters independent of other factors. CONCLUSIONS: Among US adult inpatients administered NMBs, we observed complex relationships between patient, site, procedural characteristics, and NMB management choices as NMBA choice and active reversal options among inpatient cases changed over time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01835-2. Springer Healthcare 2021-07-28 2021 /pmc/articles/PMC8317140/ /pubmed/34319550 http://dx.doi.org/10.1007/s12325-021-01835-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Bash, Lori D.
Turzhitsky, Vladimir
Black, Wynona
Urman, Richard D.
Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings
title Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings
title_full Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings
title_fullStr Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings
title_full_unstemmed Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings
title_short Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings
title_sort neuromuscular blockade and reversal agent practice variability in the us inpatient surgical settings
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317140/
https://www.ncbi.nlm.nih.gov/pubmed/34319550
http://dx.doi.org/10.1007/s12325-021-01835-2
work_keys_str_mv AT bashlorid neuromuscularblockadeandreversalagentpracticevariabilityintheusinpatientsurgicalsettings
AT turzhitskyvladimir neuromuscularblockadeandreversalagentpracticevariabilityintheusinpatientsurgicalsettings
AT blackwynona neuromuscularblockadeandreversalagentpracticevariabilityintheusinpatientsurgicalsettings
AT urmanrichardd neuromuscularblockadeandreversalagentpracticevariabilityintheusinpatientsurgicalsettings